Introduction. Assessing Antidepressant Efficacy: A Reexamination

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

While treatment outcome has improved in patients with depressive and anxiety disorders since the introduction of the newer antidepressants including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin-norepinephrine reuptake inhibitors (SNRIs), some special populations and those with specific subtypes of depression often remain treatment refractory. Also, some patients respond partially and continue to experience symptoms of depression. The purpose of this Supplement is to reexamine the issue of efficacy and completeness of response to antidepressant treatment.’ ‹